Clinical trial
A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
NCT07357415 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- January 24, 2026
- Completion date
- November 30, 2028
- Enrollment
- 600 (estimated)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.